Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948373323> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2948373323 abstract "Vascular endothelial growth factor C (VEGFC) promotes tumor progression in several tumor types, mainly through the stimulation of lymphangiogenesis and lymphatic metastasis. The expression and biological significance of the VEGFCNEGFR3 pathway in ovarian cancer growth and dissemination has been investigated in this thesis using ovarian carcinoma cell lines and tumor animal models. In patient-derived ovarian carcinoma xenografts (HOC), high levels of soluble VEGFC in ascites and serum were detected, in association with disease progression and tumor burden. Peak VEGFC expression preceded para-aortic lymph node infiltration by HOCS neoplastic cells. Histological detection of tumor cells in blood and lymphatic vessels indicated both hematogenous and lymphatic dissemination. VEGFC was over-expressed in the VEGFR3-positive and luciferase-expressing 1A9 and IGROV1 ovarian cancer cells. In vitro, VEGFC released by the expressing turnor cells stimulated turnor cell migration in an autocrine manner. In vivo, over-expression of VEGFC promoted . IGROVl dissemination after orthotopic intraovarian transplantation in nude mice. VEGFC released in serum of mice correlated with tumor burden and metastasis. Cediranib, a small molecule receptor tyrosine kinase inhibitor of VEGFR1-3 and c-Kit, inhibited in vivo metastasis of VEGFC-overexpressing [GROVI and in vitro autocrine effects on turnor cell migration; cediranib improved the survival of mice bearing the four HOC xenografts analyzed. The therapeutic benefit was proportional to soluble VEGFC levels in serum and ascites and to VEGFR3 expression by tumor cells. Different schedules of cediranib were tested on HOC8 xenograft, The survival benefit of cediranib in maintenance regimen (14 weeks) was superior to 3-weeks treatment. A significant prolongation of mice survival was observed in mice treated with advanced tumor. Treatment benefits were improved combining cediranib with chemotherapy (paclitaxel plus cisplatin). These findings suggest that the VEGFC/VEGFR3 pathway acts as an enhancer of ovarian cancer progression through autocrine and paracrine mechanisms, hence offering a potential target for therapy." @default.
- W2948373323 created "2019-06-14" @default.
- W2948373323 creator A5081134774 @default.
- W2948373323 date "2013-01-01" @default.
- W2948373323 modified "2023-09-28" @default.
- W2948373323 title "The VEGFC/VEGFR3 pathway in the malignancy of ovarian carcinoma" @default.
- W2948373323 doi "https://doi.org/10.21954/ou.ro.0000eef4" @default.
- W2948373323 hasPublicationYear "2013" @default.
- W2948373323 type Work @default.
- W2948373323 sameAs 2948373323 @default.
- W2948373323 citedByCount "0" @default.
- W2948373323 crossrefType "dissertation" @default.
- W2948373323 hasAuthorship W2948373323A5081134774 @default.
- W2948373323 hasConcept C103041312 @default.
- W2948373323 hasConcept C121608353 @default.
- W2948373323 hasConcept C126322002 @default.
- W2948373323 hasConcept C128240485 @default.
- W2948373323 hasConcept C146285616 @default.
- W2948373323 hasConcept C167734588 @default.
- W2948373323 hasConcept C170493617 @default.
- W2948373323 hasConcept C2776636583 @default.
- W2948373323 hasConcept C2777025900 @default.
- W2948373323 hasConcept C2779013556 @default.
- W2948373323 hasConcept C2779256057 @default.
- W2948373323 hasConcept C2780427987 @default.
- W2948373323 hasConcept C3019054536 @default.
- W2948373323 hasConcept C502942594 @default.
- W2948373323 hasConcept C71924100 @default.
- W2948373323 hasConcept C86803240 @default.
- W2948373323 hasConceptScore W2948373323C103041312 @default.
- W2948373323 hasConceptScore W2948373323C121608353 @default.
- W2948373323 hasConceptScore W2948373323C126322002 @default.
- W2948373323 hasConceptScore W2948373323C128240485 @default.
- W2948373323 hasConceptScore W2948373323C146285616 @default.
- W2948373323 hasConceptScore W2948373323C167734588 @default.
- W2948373323 hasConceptScore W2948373323C170493617 @default.
- W2948373323 hasConceptScore W2948373323C2776636583 @default.
- W2948373323 hasConceptScore W2948373323C2777025900 @default.
- W2948373323 hasConceptScore W2948373323C2779013556 @default.
- W2948373323 hasConceptScore W2948373323C2779256057 @default.
- W2948373323 hasConceptScore W2948373323C2780427987 @default.
- W2948373323 hasConceptScore W2948373323C3019054536 @default.
- W2948373323 hasConceptScore W2948373323C502942594 @default.
- W2948373323 hasConceptScore W2948373323C71924100 @default.
- W2948373323 hasConceptScore W2948373323C86803240 @default.
- W2948373323 hasLocation W29483733231 @default.
- W2948373323 hasOpenAccess W2948373323 @default.
- W2948373323 hasPrimaryLocation W29483733231 @default.
- W2948373323 hasRelatedWork W1826592847 @default.
- W2948373323 hasRelatedWork W1979242769 @default.
- W2948373323 hasRelatedWork W1982903140 @default.
- W2948373323 hasRelatedWork W1984526761 @default.
- W2948373323 hasRelatedWork W2003321853 @default.
- W2948373323 hasRelatedWork W2007663426 @default.
- W2948373323 hasRelatedWork W2022130531 @default.
- W2948373323 hasRelatedWork W2041507605 @default.
- W2948373323 hasRelatedWork W2055101619 @default.
- W2948373323 hasRelatedWork W2061929353 @default.
- W2948373323 hasRelatedWork W2067005226 @default.
- W2948373323 hasRelatedWork W2111452613 @default.
- W2948373323 hasRelatedWork W2282167250 @default.
- W2948373323 hasRelatedWork W2317026286 @default.
- W2948373323 hasRelatedWork W2317906450 @default.
- W2948373323 hasRelatedWork W2340483368 @default.
- W2948373323 hasRelatedWork W2562025158 @default.
- W2948373323 hasRelatedWork W2754482101 @default.
- W2948373323 hasRelatedWork W2950979380 @default.
- W2948373323 hasRelatedWork W3034805736 @default.
- W2948373323 isParatext "false" @default.
- W2948373323 isRetracted "false" @default.
- W2948373323 magId "2948373323" @default.
- W2948373323 workType "dissertation" @default.